Literature DB >> 17892885

Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research.

Helen Blair Simpson1, Eva Petkova, Jianfeng Cheng, Jonathan Huppert, Edna Foa, Michael R Liebowitz.   

Abstract

Longitudinal clinical trials in psychiatry have used various statistical methods to examine treatment effects. The validity of the inferences depends upon the different method's assumptions and whether a given study violates those assumptions. The objective of this paper was to elucidate these complex issues by comparing various methods for handling missing data (e.g., last observation carried forward [LOCF], completer analysis, propensity-adjusted multiple imputation) and for analyzing outcome (e.g., end-point analysis, repeated-measures analysis of variance [RM-ANOVA], mixed-effects models [MEMs]) using data from a multi-site randomized controlled trial in obsessive-compulsive disorder (OCD). The trial compared the effects of 12 weeks of exposure and ritual prevention (EX/RP), clomipramine (CMI), their combination (EX/RP&CMI) or pill placebo in 122 adults with OCD. The primary outcome measure was the Yale-Brown Obsessive Compulsive Scale. For most comparisons, inferences about the relative efficacy of the different treatments were impervious to different methods for handling missing data and analyzing outcome. However, when EX/RP was compared to CMI and when CMI was compared to placebo, traditional methods (e.g., LOCF, RM-ANOVA) led to different inferences than currently recommended alternatives (e.g., multiple imputation based on estimation-maximization algorithm, MEMs). Thus, inferences about treatment efficacy can be affected by statistical choices. This is most likely when there are small but potentially clinically meaningful treatment differences and when sample sizes are modest. The use of appropriate statistical methods in psychiatric trials can advance public health by ensuring that valid inferences are made about treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892885      PMCID: PMC3905985          DOI: 10.1016/j.jpsychires.2007.07.012

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  26 in total

1.  Analyzing incomplete longitudinal clinical trial data.

Authors:  Geert Molenberghs; Herbert Thijs; Ivy Jansen; Caroline Beunckens; Michael G Kenward; Craig Mallinckrodt; Raymond J Carroll
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

2.  Marginal analysis of incomplete longitudinal binary data: a cautionary note on LOCF imputation.

Authors:  Richard J Cook; Leilei Zeng; Grace Y Yi
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

Review 3.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

Authors:  Ralitza Gueorguieva; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2004-03

4.  Missing data in longitudinal studies.

Authors:  N M Laird
Journal:  Stat Med       Date:  1988 Jan-Feb       Impact factor: 2.373

5.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

6.  Models for longitudinal data: a generalized estimating equation approach.

Authors:  S L Zeger; K Y Liang; P S Albert
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

7.  Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study.

Authors:  R D Marshall; K L Beebe; M Oldham; R Zaninelli
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

8.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.

Authors:  D H Barlow; J M Gorman; M K Shear; S W Woods
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

9.  Coping with missing data in clinical trials: a model-based approach applied to asthma trials.

Authors:  James Carpenter; Stuart Pocock; Carl Johan Lamm
Journal:  Stat Med       Date:  2002-04-30       Impact factor: 2.373

10.  Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.

Authors:  H Blair Simpson; Michael R Liebowitz; Edna B Foa; Michael J Kozak; Andrew B Schmidt; Vivienne Rowan; Eva Petkova; Kevin Kjernisted; Jonathan D Huppert; Martin E Franklin; Sharon O Davies; Raphael Campeas
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

View more
  4 in total

1.  Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa.

Authors:  James Lock; Daniel Le Grange; W Stewart Agras; Ann Moye; Susan W Bryson; Booil Jo
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults.

Authors:  Kathryn Ponniah; Iliana Magiati; Steven D Hollon
Journal:  J Obsessive Compuls Relat Disord       Date:  2013-04-01       Impact factor: 1.677

3.  Missing Data in Longitudinal Trials - Part B, Analytic Issues.

Authors:  Juned Siddique; C Hendricks Brown; Donald Hedeker; Naihua Duan; Robert D Gibbons; Jeanne Miranda; Philip W Lavori
Journal:  Psychiatr Ann       Date:  2008-12-01

4.  Teens Taking Charge: A Randomized Controlled Trial of a Web-Based Self-Management Program With Telephone Support for Adolescents With Juvenile Idiopathic Arthritis.

Authors:  Jennifer N Stinson; Chitra Lalloo; Amos S Hundert; Sarah Campillo; Tania Cellucci; Paul Dancey; Ciaran Duffy; Janet Ellsworth; Brian M Feldman; Adam M Huber; Nicole Johnson; Geert't Jong; Kiem Oen; Alan M Rosenberg; Natalie J Shiff; Lynn Spiegel; Shirley M L Tse; Lori Tucker; Joseph Charles Victor
Journal:  J Med Internet Res       Date:  2020-07-29       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.